• Business development and licensing (BD&L)

     

    We’re focused on identifying breakthrough science and collaborating together to make the greatest difference for patients, now and in the future.

Partnering interests

Oncology

Advanced or metastatic solid tumors

Urothelial carcinoma
Esophageal
Head & Neck
Pancreatic

Enabling/platform technologies

Responsible for the portfolio strategy of the Company’s innovation pipeline as well as the planning, development and implementation of partnering strategy.

Partner with us

Via external partnering Conjustar aim to accelerate the clinical development and commercialization of its innovative products so as to benefit patients in China and eventually worldwide as soon as possible. We warmly welcome any inquiries from domestic and overseas partners who are in great strategic/product synergies with us.

nt sites in Shanghai and Zhuhai.

Learn more about our team

 

We aim to accelerate the clinical development  and commercialization of our pipeline through external cooperation, so as to benefit more patients in China and global as soon as possible. 

Conjustar proactively embraces external partnering opportunities in Chinese and overseas markets. At present we are open for various cooperation modes such as out-licensing, co-development, CSO/distribution partnership, strategic alliances (including equity investment) through the clinical-stage products/projects on our innovation pipeline.